

## CLAIMS

1. A method of polyubiquitinating a nucleophosmin comprising of reacting the nucleophosmin with BRCA1-BARD1.
2. A method of stabilizing a nucleophosmin comprising of polyubiquitination of nucleophosmin.
3. The method of Claim 1 or 2, wherein polyubiquitination is carried out *in vitro* or *in vivo*.
4. A method of inhibiting polyubiquitination of nucleophosmin comprising of phosphorylating BARD1 using CDK2-cyclin E or CDK2-cyclin A.
5. A method of degrading and/or dissociating BRCA1-BARD1 comprising of phosphorylating BARD1 using CDK2-cyclin E and/or CDK2-cyclin A.
6. A method of inactivating ubiquitin ligase activity of a BRCA1-BARD1 comprising of phosphorylating BARD1 using CDK2-cyclin E and/or CDK2-cyclin A.
7. The method according to any one of Claims 4 to 6 wherein the phosphorylation sites of BARD1 are at least three sites selected from the group consisting of S148, S251, S288 and T299.
8. The method according to any one of Claims 4 to 6 wherein the phosphorylation sites of BARD1 are S148, S288 and T299.
9. The method according to any one of Claims 4 to 6 wherein the phosphorylation sites of BARD1 are S148, S251, S288 and T299.
10. A method of transporting BRCA1 from a nucleus to cytoplasm wherein BRCA1 and CDK2-cyclin E and/or CDK2-cyclin A are co-expressed.